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doi:10.101A Randomized Phase II Trial Comparing Tacrolimus
and Mycophenolate Mofetil to Tacrolimus
and Methotrexate for Acute Graft-versus-Host
Disease Prophylaxis
Janelle Perkins,1,2 Teresa Field,1,2 Jongphil Kim,2,3 Mohamed A. Kharfan-Dabaja,1,2
Hugo Fernandez,1,2 Ernesto Ayala,1,2 Lia Perez,1,2 Mian Xu,1 Melissa Alsina,1,2
Leonel Ochoa,1,2 Daniel Sullivan,1,2 William Janssen,1,2 Claudio Anasetti1,2Tacrolimus (Tac) plus methotrexate (MTX) is a standard regimen for graft-versus-host disease (GVHD)
prophylaxis. Mycophenolate mofetil (MMF) is sometimes used instead of MTX to minimize toxicity, despite
the lack of controlled studies demonstrating efficacy.We conducted a single-center, randomized phase II trial
comparing Tac 1 MMF to Tac 1 MTX. Intent-to-treat analyses included 42 patients randomized to Tac 1
MMF and 47 to Tac 1 MTX. Patient characteristics were not different between the study arms. Patients in
the Tac1MMF armwere less likely to experience severemucositis, require narcotic analgesia and parenteral
nutrition, and had earlier hospital discharge. The Tac1MMF arm had the same time to neutrophil recovery,
but earlier platelet recovery. The cumulative incidence of grade II-IV acute GVHD (aGVHD) at 100 days was
similar (P5 .8), but grade III-IV aGVHD was higher in the Tac1MMF arm (19% versus 4%; P5 .03); this was
predominantly seen in unrelated donor transplants (26% versus 4%; P5.04), and less in related donor trans-
plants (11% versus 4%; P 5 n.s.). Moderate or severe chronic GVHD was similar (P 5 .71). There were
no significant differences between the arms in relapse, nonrelapse mortality, or overall and relapse-free
survivals. MMF was associated with less early toxicity than MTX but was not as effective in preventing severe
aGVHD, especially in unrelated donor transplants.
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Acute graft-versus-host disease (aGVHD) is a sig-
nificant complication of allogeneic hematopoietic cell
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imately 10% to 20% of patients. Because treatment of
established aGVHD can be difficult, the use of
effective prophylaxis is of paramount importance.
Tacrolimus (Tac), a potentmacrolide lactone immuno-
suppressant, has been evaluated in combination with
methotrexate (MTX) and found to be superior to cyclo-
sporine (CsA) withMTX in the prevention of aGVHD
in both sibling and unrelated donor transplants [1-3].
Based on these data, Tac 1 MTX has become the
standard prophylactic regimen in many transplant
centers. However, Tac 1 MTX prophylaxis is
ineffective in many patients. Furthermore, MTX is
associated with a number of adverse outcomes,
including severe mucositis, delays in neutrophil and
platelet recovery, and renal, pulmonary, and hepatic
toxicity. In addition, MTX administration is limited
by renal dysfunction or ‘‘third spacing’’ because of
prolonged elimination times, resulting in increased
risk of toxicity. Often, doses of MTXmust be omitted,
which may further jeopardize the efficacy of GVHD
prophylaxis. Although some transplant centers have937
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prophylaxis [4], others have evaluated alternative im-
munosuppressive agents with the goal of finding a safer
and perhaps more efficacious regimen.
Mycophenolate mofetil (MMF) has been utilized
in an effort to improve GVHD prophylaxis and
reduce toxicity. MMF is an ester prodrug of the im-
munosuppressant mycophenolic acid. Mycophenolic
acid inhibits inosine monophosphate dehydroge-
nase, resulting in the blockade of de novo purine
synthesis, thereby limiting proliferation of lympho-
cytes [5]. MMF is effective in preventing GVHD
in canine models, and the combination of CsA 1
MMF is more effective than either agent alone [6].
The CsA 1MMF or Tac 1MMF combinations are
commonly used as GVHD prophylaxis in patients
undergoing nonmyeloablative (NMA) transplants.
MMF has been compared to MTX in 2 small pro-
spective randomized studies in combination with
CsA as GVHD prophylaxis in patients undergoing
myeloablative (MA) transplant [7,8]. In the study
reported by Bolwell et al. [7], significant benefits
were seen in the MMF arm, including less severe
mucositis, shorter time to neutrophil and platelet
engraftment, a reduction in use of total parenteral
nutrition (TPN) and narcotic analgesia, and shorter
hospitalization times, resulting in early termination
of the trial. No differences were observed in the in-
cidence of GVHD or survival, but the analysis
lacked sufficient power to detect significant differ-
ences in these outcomes. The second study by Kiehl
et al. [8] compared CsA 1 MTX 6 prednisone to
CsA 1 MMF 6 prednisone; this study also demon-
strated a reduction in severe mucositis and time to
engraftment in the MMF arm. They observed no
difference in the incidence and severity of aGVHD
between patients treated with 2 g/day of MMF and
those receiving MTX; patients receiving 3 g/day of
MMF had a slightly higher incidence of grade III-
IV aGVHD than the other groups. The combina-
tion of Tac 1 MMF has been evaluated as GVHD
prophylaxis in both adults and children in single-
arm phase II trials after MA or NMA regimens.
These studies have shown TAC 1 MMF to be
well tolerated when compared to prior experience
[9-12].
Here, we report results of a prospective, single-
center, randomized controlled trial comparing Tac 1
MTX to Tac 1 MMF as GVHD prophylaxis. The
primary objective was to compare the incidence of
severe mucositis between the 2 prophylactic regi-
mens; the secondary objectives were to generate
preliminary data on aGVHD and chronic GVHD
(cGVHD), engraftment, treatment-related morbidity
and mortality, T cell turnover, relapse, and overall
survival (OS).PATIENTS AND METHODS
Patients
Patients undergoing allogeneic HCT from sibling
or unrelated donors matched for 10/10 or 9/10 human
leukocyte antigen (HLA)-A, -B, -C, -DRB1, and
- DQB1 alleles were eligible for this study. The proto-
col was approved by the University of South Florida
institutional review board, and all patients signed in-
formed consent documents. Patients were randomized
to Tac 1 MTX or Tac 1MMF (1:1) via the Interac-
tive Voice Randomization System coordinated by the
Bioinformatics Department of the Moffitt Cancer
Center. Randomization was stratified based on prede-
fined conditioning regimen intensity. Enrollment
occurred between 10/26/05 and 1/31/08, and data
analysis reported is as of 1/31/09.Study Treatment
Tacrolimus
All patients received Tac 0.03 mg/kg/day as a 24-
hour continuous intravenous (i.v.) infusion beginning
on day 23 (day 0 being the anticipated day of HCT).
Tac dosing was based on ideal body weight. When
the patient was able to tolerate oral medications, the
i.v. Tac was converted to oral dosing given twice daily.
Tac doses were adjusted to maintain whole blood
levels of 5-15 ng/mL. Full-dose Tac was to be given
until day160 (67) when tapering was begun in the ab-
sence of GVHD. Provided no GVHD developed, Tac
was to be discontinued on day 1180 (614). Tapering
schedules were modified at the discretion of the treat-
ing physician in the case of relapse/persistence of ma-
lignancy or presence of GVHD. Early discontinuation
of Tac was considered in the event of thrombotic mi-
croangiopathy (TMA) or posterior reversible enceph-
alopathy syndrome.
Methotrexate
Patients randomized to Tac 1 MTX received 15
mg/m2 i.v. on posttransplant day 11, then 10 mg/m2
i.v. on days 13, 16, and 111. Per institutional prac-
tice, doses were reduced in patients with renal insuffi-
ciency defined as a pretransplant measured creatinine
clearance below the lower limits of normal (75 mL/
min in women and 95 mL/min in men). In these pa-
tients, MTX dosing was reduced in proportion to
reduction in creatinine clearance below the median
of the normal range (95 mL/min for women and 120
mL/min for men). In addition, MTX dosing was
stopped or reduced if patients developed impending
oropharyngeal obstruction because of severe mucosi-
tis, fluid ‘‘third spacing’’ (eg, pleural effusions or asci-
tes), or severe liver dysfunction.
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Patients randomized to MMF received 30 mg/kg/
day i.v. in 2 divided doses beginning day 0 at least 2
hours after the end of the infusion of donor cells. Dos-
ing was based on the lesser of adjusted ideal body
weight or actual body weight. The i.v. dose was con-
verted to the oral formulation as patients were able
to tolerate oral medications. In the absence of
GVHD, a tapering schedule was to begin on day
1240 (614) and to be completed on day 1360
(614). Tapering schedules were modified at the dis-
cretion of the treating physician in the case of relapse/
persistence of malignancy or presence of GVHD.
MMF dosing could be stopped or reduced in the
setting of neutropenia or severe gastrointestinal symp-
toms if no other cause was identified.Preparative Regimens, Hematopoietic Cell
Infusions, and Supportive Care
The majority of patients received fludarabine
40 mg/m2/day daily for 4 days, followed each day by
i.v. busulfan (Bu/Flu) pharmacokinetically targeted to
an AUC of 3500, 5300, or 6000 mmol*min/L per day,
depending on patient age, comorbidities, and disease
risk. Bu targeted to 3500mmol*min/L per daywas given
to patients over the age of 65 years, over 60 if comorbid-
ities were present, and to patients with chronic lympho-
cytic leukemia. Patients receiving Bu targeted to 6000
mmol*min/L per day were coenrolled on a prospective
study evaluating increasing AUCof Bu. The remainder
of the patients were treated to a Bu target of 5300
mmol*min/L per day. Other regimens included Flu
40 mg/m2/day daily for 4 days followed on the last 2
days by melphalan 70 mg/m2/day (Flu/Mel), Flu
30 mg/m2/day for 3 days, and total body irradiation
(TBI) 200 cGy (Flu/TBI), and IV Bu daily for 4 days
with cyclophosphamide 60 mg/kg/day for 2 days (Bu/
Cy). Three patients in the MMF arm and 1 patient in
the MTX arm receiving grafts from HLA mismatched
donors received Thymoglobulin 7.5 mg/kg over 3
days through day21. One patient with aplastic anemia
with previous exposure to ATG received alemtuzumab
30 mg over 3 days through day –3, as part of condition-
ing. Two patients in each arm with CD20-positive
lymphoid malignancies received rituximab as part of
conditioning.
All patients received peripheral blood stem cells
(PBSCs) collected from donors who had received fil-
grastim for priming. Ex vivo T cell depletion was not
performed. Hematopoietic cells were infused on day 0.
Antimicrobial prophylaxis consisted of acyclovir,
levofloxacin, and either fluconazole or voriconazole.
Cytomegalovirus (CMV) was assayed weekly by real-
time polymerase chain reaction of blood samples;
when positive, patients were treated with preemptive
ganciclovir, valganciclovir, or foscarnet.Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis infection
was given at least twice weekly. Broad-spectrum antibi-
otics were administered for febrile neutropenic episodes
with antifungal therapy added as clinically indicated.
Patient-controlled analgesia (PCA) was initiated in
patients with severe pain because of mucositis; TPN
was administered if patients were unable to meet their
nutritional needs.Ursodiol 600-900mg/day (depending
on body weight) was given at the start of conditioning
through day 80 to prevent hepatotoxicity. Patients did
not routinely receive myeloid growth factors in the
immediate posttransplant period. Platelet and/or red
blood cell transfusions were given for platelet counts
of \10  109/L or hemoglobin \8 g/dL. All blood
products were leukocyte filtered and irradiated for all
patients; CMV-negative donors were selected for
CMV-negative recipients.
Treatment of GVHD was at the discretion of the
treating physician based on the severity of GVHD
symptomatology. Initial treatment of stage 1-2 skin
GVHD usually consisted of topical corticosteroid
preparations. Beclomethasone and budesonide were
also used as topical therapy for upper and lower gastro-
intestinal symptoms, respectively. Prednisone (1-2mg/
kg/day or equivalent) was initiated for treatment of
grade II or higher GVHD. Prophylactic agents were
continued, and other immunosuppressive agents were
added if symptoms were not controlled on corticoste-
roid therapy or to assist in tapering of corticosteroids.
Endpoint Definition and Assessment
Mucositis
Mucositis was assessed prospectively daily while
the patient was hospitalized and graded retrospectively
based on nurse and clinician assessments according to
the clinical criteria set forth in theNational Cancer In-
stitute Common Terminology Criteria for Adverse
Events (CTCAE; version 3.0). Start and stop dates
for TPN and PCA were recorded. Length of hospital-
ization was measured from the date of transplant to the
date of discharge.
GVHD
Patients were assessed for aGVHD at least weekly
until day 100 posttransplant. aGVHD was staged by
individual organ and graded according to consensus
conference criteria [13]. Skin, intestinal, and/or liver
biopsies were obtained, when appropriate, to facilitate
the diagnosis. After day 100, patients were assessed at
least every 3months for cGVHD. cGVHDwas graded
as mild, moderate, or severe based on the National
Institutes of Health Consensus Development Project
[14]. Patients were censored for the assessment of
GVHD at the time of relapse or death. The type and
duration of immunosuppressive treatment given for
GVHD were recorded. Prophylactic agents were
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they were continued or restarted beyond the diagnosis
of GVHD.
Transplant-related organ toxicity and
engraftment
Patients were assessed at least weekly until day 100
posttransplant for organ toxicity. Transplant-related
organ toxicity was graded using CTCAE version 3.0.
Hepatic veno-occlusive disease (also called sinusoidal
obstructive syndrome) was diagnosed and staged ac-
cording to criteria set forth by McDonald et al. [15].
Day of neutrophil engraftment was defined as the first
of 3 consecutive days posttransplant that the absolute
neutrophil count was .500/mm3. Day of platelet en-
graftment was defined as the first of 3 consecutive
platelet count measurements at least 24 hours apart
that the platelet count was .20,000/mm3 without
platelet transfusion in the preceding 7 days. Donor
chimerism was assessed by analysis of single-tandem
repeats on whole marrow and in sorted CD31 T cells
and CD331 granulocytes from the blood on or about
days 130, 190, and 1365.
T cell turnover
Blood samples were collected on or about day 30,
day 100, and 1 year posttransplant and tested for ex-
pression of Ki-67 onCD4 andCD8T lymphocytes us-
ing CD8-FITC, CD4-APC, CD45-PerCP antibodies,
and the Ki-67-phycoerythrin-conjugated reagent set
(BD Biosciences, San Diego, CA). Ki-67 expression
in the gated CD41 or CD81 populations was based
in comparison to cells stained with isotype-matched
phycoerythrin-tagged antibody that gave\0.5% back-
ground. All samples were analyzed using a FACSCali-
bur flow cytometer and CellQuest software (both from
BD Biosciences, San Jose, CA). Absolute CD41/Ki-
671 (or other subset) counts were calculated by multi-
plying the fraction of CD41/Ki-671 (or other subset)
events among the CD451 events by the absolute white
blood cell (WBC) count.
Nonrelapse mortality (NRM) and survival
NRM was defined as death from any cause in pa-
tients who have no evidence of malignancy at the
time of death. Survival was measured from the time
of transplant to the time of last contact or death. All pa-
tients were followed for at least 1 year or until death,
whichever occurred first.Statistical Analysis
Sample size determination
Sample size was based on the difference in the pro-
portion of patients in each arm who were predicted to
develop severe mucositis defined as clinical grade 3 or4 per the CTCAE. A sample-size of 42 evaluable sub-
jects per study-arm allowed detection of an absolute
difference of 30%, which corresponds to a reduction
in the incidence of severe mucositis from 60% in the
methotrexate arm to 30% in the MMF arm (alpha 5
0.05, power 5 0.80). The absolute difference of 30%
was based on that reported by Bolwell et al. [7] and
Kiehl et al. [8].
Analysis of endpoints
All analyses were performed on an intent-to-treat
basis. Categoric variables are summarized as frequen-
cies or percentages and compared between groups us-
ing the ‘‘N2 1’’ chi-squared test for 2 2 table [16] or
Fisher’s exact test for the other cases. Continuous vari-
ables are summarized as the median and range and
compared between groups using the Wilcoxon rank-
sum test. OS and relapse-free survival (RFS) are esti-
mated using the Kaplan-Meier method and compared
between groups using the log-rank test. Cumulative
incidences of time to engraftment, aGVHD and
cGVHD, as well as relapse and NRM are generated
based on the life-table method and compared using
the method of Gray [17].RESULTS
Patients and Transplant Characteristics
Ninety-two patients were enrolled on the study; 45
were randomized to Tac 1 MMF and 47 to Tac 1
MTX. Two Tac 1 MMF patients were not trans-
planted and 1 withdrew consent prior to receiving
treatment; therefore, 42 Tac1 MMF patients and
47 Tac 1 MTX patients are included in the analyses.
One patient in each arm received the other regimen;
however, all the analyses are based on intent to treat.
No significant differences were found in patient and
transplant characteristics between the study arms
(Table 1). Acutemyelogenous leukemia andmyelodys-
plastic syndrome were the most common diagnoses.
Ninety percent of patients received conditioning
with Flu and MA doses of Bu (AUC targeted to 5300
mmol*min/L per day or greater). Twenty-three pa-
tients in each arm received allografts from unrelated
donors.
Regimen Compliance
Tacrolimus
One (2%) Tac1MMF patient and 6 Tac1MTX
(13%) patients had Tac discontinued because of ele-
vated creatinine, thrombocytopenia, elevated lactate
dehydrogenase (LDH), anemia, or red blood cell
(RBC) abnormalities consistent with TMA (P 5 .07).
Two (4%) Tac 1 MMF patients and 1 (2%) Tac 1
MTX patient without GVHD were able to begin
Table 1. Patient and Transplant Characteristics
Tac + MTX (n 5 47) Tac + MMF (n 5 42) P
Median age, years (range) 51.1 (24.9-69.6) 49.9 (23.0-66.2) .19
Sex (male:female) 29:18 21:21 .27
Diagnosis .50
ALL 4 (8%) 4 (10%)
AML 14 (30%) 19 (45%)
CLL/NHL/HD 5 (11%) 7 (17%)
CML 4 (9%) 1 (2%)
MDS/MF 14 (30%) 9 (22%)
MM 3 (6%) 1 (2%)
Other 3 (6%) 1 (2%)
Disease risk* 1.00
Low 23 (49%) 18 (43%)
Intermediate 7 (15%) 8 (19%)
High 17 (36%) 16 (38%)
CMV recipient/donor serostatus .92
Positive/positive 15 (32%) 15 (36%)
Positive/negative 16 (34%) 14 (33%)
Negative/negative 12 (25%) 11 (26%)
Negative/positive 4 (9%) 2 (5%)
Recipient/donor gender .38
Male/male 19 (41%) 14 (33%)
Male/female 10 (21%) 7 (17%)
Female/male 9 (19%) 15 (36%)
Female/female 9 (19%) 6 (14%)
Donor .83
Matched related 24 (51%) 19 (45%)
Matched unrelated 21 (45%) 20 (48%)
Mismatched unrelated 2 (4%) 3 (7%)
Conditioning regimen .37
BuFlu (Bu AUC 6000) 9 (19%) 8 (19%)
BuFlu (Bu AUC <6000)† 37 (79%) 30 (71%)
Other‡ 1 (2%) 4 (10%)
Median number of CD34+ cells infused (106)/kg (range) 7.5 (4.2-10.1) 7.8 (2.2-10.3) .66
AML indicates acute myelogenous leukemia; AUC, area under the curve; Bu/Flu, fludarabine followed by busulfan; MDS, myelodysplastic syndrome;
MTX, methotrexate; Tac, tacrolimus.
*Per CIBMTR classification.
†Three MTX and 1 MMF patient received busulfan targeted to AUC 3500; the remainder were targeted to 5300.
‡One MTX and 2 MMF patients received fludarabine/melphalan, 1 MMF patient received busulfan/cyclophosphamide, and 1 MMF patient received
fludarabine/total body irradiation 200 cGy.
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whereas the rest required prolonged therapy for
GVHD manifestations (P 5 .49). At the time of anal-
ysis, 7 (17%) Tac 1 MMF patients and 8 (17%) Tac
1 MTX patients discontinued Tac in the absence of
GVHD (P 5 .96).
MTX
Twenty-one of the 47 patients (45%) had MTX
doses reduced per protocol for pretransplant renal in-
sufficiency. MTX was not given to 1 (2%) patient on
days 6 and 11 because of hepatic injury, and 9 (20%)
patients had their day 11 dose withheld because of se-
vere mucositis. Eight of these patients were started on
MMF on day 11 as substitute for GVHD prophylaxis.
MMF
Nine of the 42 patients (21%) had doses tapered or
discontinued secondary to cytopenias or gastrointesti-
nal side effects. Four patients (10%) without evidence
of GVHD had MMF tapered around day 240 accord-
ing to the protocol. Seven (17%) patients stoppedMMF in the absence of GVHD after day 240, whereas
the remaining surviving patients continue on MMF.Outcomes
Mucositis and early morbidity
Patients on the Tac 1MMF arm had lower mean
grades of mucositis (P\ .05, Figure 1). The difference
in mucositis scores was significant from day 13 until
day 20 posttransplant. There was suggestion for
a lower incidence (33% versus 53%; P 5 .06) and
shorter duration (median 0 day versus 1 day; P 5 .05)
of grade 3 or 4 mucositis in the MMF arm. Fewer
patients in the Tac 1 MMF arm required PCA for
mucositis pain (64% versus 89%; P 5 .005), and the
duration of PCA use was shorter in the Tac 1 MMF
arm (median 5 days versus 7 days; P 5 .05). Fewer pa-
tients in the Tac 1 MMF arm required TPN (36%
versus 60%; P 5 .03). The length of hospitalization
after transplant was also shorter in patients random-
ized to Tac 1 MMF (median 17 days versus 19 days;
P5 .04). One patient in each arm developed moderate
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Figure 1. Mean CTCAE grade of oral mucositis. Vertical lines repre-
sent 95% confidence levels for the mean grades. Asterisks are placed
on days when the difference in the mean grades were statistically
significant (P\.05).
Table 2. Distribution of Maximum Acute GVHD Grading
Tac + MTX (n 5 47) Tac + MMF (n 5 42) P
Overall .01
0 5 (11%) 0 (0%)
1 5 (11%) 9 (21%)
2 35 (74%) 25 (60%)
3 1 (2%) 6 (14%)
4 1 (2%) 2 (5%)
Skin .02
0 26 (55%) 11 (26%)
1 13 (28%) 23 (55%)
2 6 (13%) 7 (17%)
3 2 (4%) 1 (2%)
4 0 (0%) 0 (0%)
Liver .22
0 47 (100%) 40 (96%)
1 0 (0%) 0 (0%)
2 0 (0%) 1 (2%)
3 0 (0%) 0 (0%)
4 0 (0%) 1 (2%)
Upper GI .82
0 15 (32%) 14 (33%)
1 32 (68%) 28 (67%)
Lower GI .50
0 27 (58%) 23 (55%)
1 17 (36%) 13 (31%)
2 2 (4%) 2 (5%)
3 0 (0%) 3 (7%)
4 1 (2%) 1 (2%)
GI indicates gastrointestinal; GVHD, graft-versus-host disease; MTX,
methotrexate; Tac, tacrolimus.
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cases. The 2 study arms had similar incidences of gas-
trointestinal, hematologic, hepatic, cardiac, hemor-
rhagic, and pulmonary toxicity.
Engraftment
The median day to absolute neutrophil count
greater than 500  106/L was 15 in the Tac 1 MMF
arm and 16 in the Tac1MTX arm (P5 .29). Platelet
recovery was faster in the Tac1MMF arm (median 15
days compared to 17 days; P 5 .002). There were no
graft failures in either arm. No differences were seen
between the arms in donor chimerism in marrow or
peripheral blood T cells or granulocytes (data not
shown).
T cell turnover
The number of CD4 cells at day 30 was lower in
the Tac 1 MMF patients, with a median of 154 
106/L (range: 1-602  106/L) compared to 264 
106/L (range: 3-937  106/L) (P5 .02), but no subse-
quent differences were observed. There were no differ-
ences between the arms in either the proportions of the
CD4 or CD8T cells that were positive for Ki-67 or the
absolute numbers of Ki-67-positive subsets (data not
shown). Chapuis et al. [5] reported that mycopheno-
late mofetil treatment can eliminate the fraction of
rapidly replicating, Ki-67-positive, T cells in HIV pa-
tients. Unfortunately, this effect was not observed in
this trial of PBSC transplantation.
GVHD
Maximum aGVHD overall grades were higher in
the Tac 1 MMF than in the Tac 1 MTX arm
(Table 2) (P 5 .01). At day 100, the cumulative inci-
dence of grade II-IV aGVHD was 78% for the Tac1 MMF and 79% for the Tac 1 MTX arm (P 5 .8,
Figure 2A); however, there was a higher incidence of
grade III-IV aGVHD in the Tac 1 MMF arm (19%
versus 4%; P5 .03, Figure 2B). Themajority of overall
grade II aGVHDwas accounted for by upper gastroin-
testinal symptoms, equally frequent in both arms. The
only significant difference in organ stage between the 2
study arms was the cutaneous involvement with more
Tac 1 MMF patients having stage I disease; in addi-
tion, a few more patients in the Tac 1 MMF arm
had higher stage of liver and lower gastrointestinal dis-
ease, thus accounting for the higher incidence of severe
disease overall. The difference in more severe aGVHD
(grades III-IV) was seen only in patients with unrelated
donors (26% with Tac1MMF versus 4% with Tac1
MTX; P 5 .04), whereas there was no difference in
grades III-IV aGVHD between arms in patients with
sibling donors (11%with Tac1MMF versus 4% after
Tac 1 MTX; P 5 .41, Figure 2C and D). There was
no difference in cumulative incidence of aGVHD or
cGVHD between the 37 Tac 1 MTX patients who
received all 4 doses of MTX and the 8 patients who
received 3 doses of MTX followed by substitute
MMF prophylaxis (data not shown).
The distributions of maximum cGVHD grades
were similar between the 2 arms (Table 3). The inci-
dence of moderate or severe cGVHD at 1 year was
38% in the Tac 1 MMF patients and 45% in the
Tac 1 MTX patients (P 5 .71; Figure 3). No differ-
ences in cGVHD were seen between arms when
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Figure 2. (A) Cumulative incidence of grades II-IV acute GVHD. (B) Cumulative incidence of grades III-IV acute GVHD. (C) Cumulative incidence of
grades III-IV acute GVHD in patients with unrelated donors. (D) Cumulative incidence of grades III-IV acute GVHD in patients with sibling donors.
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aGVHD was assessed weekly through day 100, and
cGVHD monthly through 1 year, there were no ap-
parent trends for longer disease duration of any degree
in 1 arm over the other (data not shown).
Most patients (83% in the Tac 1 MMF arm and
77% in the Tac 1 MTX arm) received topical treat-
ment with beclomethasone and/or budesonide for
upper and/or lower gastrointestinal GVHD, respec-
tively. Four (10%) Tac 1 MMF patients and 7
(15%)Tac1MTXpatients required no systemic ther-
apy for aGVHD or cGVHD. Of those patients who
required prednisone therapy for aGVHD or cGVHD,
28 of 38 (74%) Tac 1 MMF patients and 30 of 38
(79%) Tac 1 MTX patients received initial doses of
1 mg/kg/day, whereas 4 of 38 (11%) and 2 of 38
(5%) were treated with 2 mg/kg/day, respectively.
The remaining patients were initiated on less than 1
mg/kg/day. During the first 18months after transplan-tation, the fraction of patients on prednisone was not
different in the 2 study arms (Figure 4). Second-line
therapy for aGVHD was administered to 6 of 34
(18%) Tac 1 MMF patients and 11 of 36 (31%)
Tac 1 MTX patients who had received prednisone
as primary therapy (P 5 .41). Complete response to
second-line therapy was observed in 4 of 6 Tac 1
MMF and 7 of 11 Tac 1 MTX patients (P 5 .9) No
patients in either arm had discontinued all systemic
immunosuppressive therapy by 1 year.
Relapse and survival
The cumulative incidences of relapse (p5 .21) and
NRM (P5 .62), and the estimates of OS (P5 .58) and
RFS (P 5 .49) were similar between the arms
(Figure 5A-D). GVHD was a more common cause
of death in Tac 1 MMF patients (37% versus 12%;
P5 .05), but other causes of death, including relapsed
malignancy and infection, were similar in the 2 arms
Table 3. Distribution of Maximum Chronic GVHD Grading
Tac + MTX (n 5 37) Tac + MMF (n 5 33) P
Overall .81
None 2 (6%) 1 (3%)
Mild 12 (32%) 8 (24%)
Moderate 13 (35%) 14 (43%)
Severe 10 (27%) 10 (30%)
Skin .85
0 21 (56%) 18 (55%)
1 8 (22%) 8 (24%)
2 4 (11%) 5 (15%)
3 4 (11%) 2 (6%)
Mouth .39
0 16 (43%) 16 (48%)
1 19 (51%) 17 (52%)
2 2 (6%) 0 (0%)
3 0 (0%) 0 (0%)
Eye .15
0 22 (59%) 21 (64%)
1 11 (30%) 12 (36%)
2 4 (11%) 0 (0%)
3 0 (0%) 0 (0%)
GI .29
0 9 (24%) 9 (27%)
1 22 (59%) 13 (40%)
2 4 (11%) 6 (18%)
3 2 (6%) 5 (15%)
Liver .79
0 17 (46%) 12 (36%)
1 10 (27%) 12 (36%)
2 7 (19%) 7 (22%)
3 3 (7%) 2 (6%)
Lung .99
0 33 (88%) 29 (88%)
1 1 (3%) 1 (3%)
2 2 (6%) 2 (6%)
3 1 (3%) 1 (3%)
Joints/fascia .13
0 36 (97%) 29 (88%)
1 1 (3%) 4 (12%)
2 0 (0%) 0 (0%)
3 0 (0%) 0 (0%)
Genital tract
0 36 (97%) 31 (94%) .49
1 1 (3%) 2 (6%)
2 0 (0%) 0 (0%)
3 0 (0%) 0 (0%)
GI indicates gastrointestinal; GVHD, graft-versus-host disease; MTX,
methotrexate; Tac, tacrolimus.
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Figure 3. Cumulative incidence of moderate to severe chronic GVHD.
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944 Biol Blood Marrow Transplant 16:937-947, 2010J. Perkins et al.(Table 4). In subset analysis by donor relation, there
were no differences between the arms in relapse,
NRM, RFS, or OS. RFS and OS by donor is shown
in Figure 6A-D. The 8 Tac 1 MTX patients who
were switched to MMF had higher NRM (P 5 .05)
and lower OS (P 5 .02), but no difference in relapse
(P 5 .84), compared to those patients who received
MTX alone.0 6 12 18 24 30
0
0.1
Month Posttransplant
No. Assessed
MMF 42 31 25 16 11 6
MTX 47 30 24 16 11 7
MTX
Figure 4. Prevalence of prednisone use. Prevalence function at time t is
calculated using number of patients taking prednisone at time t divided
by number of patients who are alive and relapse free at time t.DISCUSSION
We report here the first prospective, randomized
trial comparing MMF with MTX in combination
with Tac for GVHD prophylaxis. Results demon-
strated that Tac 1 MMF is associated with a modestreduction in mucositis compared to Tac 1 MTX.
We observed faster engraftment of platelets in the
Tac 1MMF arm, but no difference in neutrophil en-
graftment. More patients in the Tac 1 MTX arm
required Tac discontinuation because of renal insuffi-
ciency or TMA, suggesting an additive nephrotoxic
effect of MTX and Tac. Other transplant-related tox-
icities were similar between the arms. A limitation of
this clinical trial is the unblinded assessment of muco-
sitis. The favorable results with less mucositis in the
Tac 1 MMF arm, however, are supported by other
objective endpoints such as shorter duration of TPN
and PCA usage as well as shorter hospitalization,
which are clinically relevant to patient comfort, quality
of life, and cost of transplantation.
The reduction in mucositis with Tac 1MMF was
seen despite several characteristics of the study popula-
tion, which predispose to increased toxicity. First,
more than 90% of patients received a regimen of Bu
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Figure 5. (A) Cumulative incidence of relapse. (B) Cumulative incidence of nonrelapse mortality. (C) Relapse-free survival. (D) Overall survival.
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and 20% of patients received intensified conditioning
with Bu targeted to 6000 mmol*min/L daily. Second,
45% of patients had pretransplant renal insufficiency.
To neutralize this factor, patients received doses of
MTX reduced in proportion to their creatinine clear-
ance, asMTX clearance approximates creatinine clear-
ance. Third, the median age of patients in this study
was 50 years, with 17%of patients over 60 years. TheseTable 4. Causes of Death
Tac + MTX N 5 25 Tac + MMF N 5 19 P
Relapse 13 (52%) 6 (32%) .18
Infection 5 (20%) 4 (21%) .93
GVHD 3 (12%) 7 (37%) .05
Other 4 (16%) 2 (10%) .60
GVHD indicates graft-versus-host disease; MTX, methotrexate; Tac,
tacrolimus.same factors predisposed patients to increased inci-
dence and severity of aGVHD.
The sample size of the study was designed to detect
a difference in mucositis between the 2 arms, but the
study was not powered to detect small differences in
GVHD or other outcomes. However, the average
grades of aGVHD and the incidence of grade III-IV
aGVHD were higher in the Tac 1MMF arm, mostly
as a result of more severe gastrointestinal and liver dis-
ease. MMF can produce gastrointestinal side effects
that can mimic GVHD symptoms. All but 4 patients
on the Tac 1MMF arm with clinical gastrointestinal
GVHD had gastrointestinal biopsies positive for
GVHD, although biopsies may not be able to differen-
tiate between MMF effect and GVHD. Among the 4
MMFpatients who experienced grade 3 or 4 lower gas-
trointestinal disease, 3 were receiving MMF orally so
that poor drug absorption may have compromised
the systemic exposure. Patients receiving Tac 1
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Figure 6. (A) Overall survival in patients with sibling donors. (B) Relapse-free survival in patients with sibling donors. (C) Overall survival in patients
with unrelated donors. (D) Relapse-free survival in patients with unrelated donors.
946 Biol Blood Marrow Transplant 16:937-947, 2010J. Perkins et al.MMF were more likely than the Tac1MTX patients
to die from GVHD, consistent with the finding that
Tac1MMF is less effective at preventing themore se-
vere forms of the disease. Any benefit of the Tac 1
MTX arm in preventing GVHD mortality, however,
was offset by higher mortality from relapse of malig-
nancy, resulting in similar overall survival between
the 2 study arms. The 2 study arms were balanced be-
tween sibling and unrelated donors, but worse GVHD
outcome was predominantly observed among patients
transplanted from unrelated donors. These transplants
lead to more frequent and intense GVHD because of
known genetic disparity for classical HLA-A, -B, -C,
and -DRB1 loci, or low expressing HLA-DRB3/4/5,
-DQB1, and -DPB1 loci that, with the exception of
DQB1, were not typed in this study [18,19]. Other
patient subsets were not analyzed.
These data demonstrate that the combination of
Tac1MMFhas the potential benefits of less early tox-icity than Tac 1 MTX. The lower potency of Tac 1
MMF in preventing severe GVHD, however, is con-
cerning especially in the setting of MA conditioning
regimens, PBSCs, and unrelated donor transplanta-
tion. Under these conditions, other forms of prophy-
laxis should be considered. Subsequent controlled
studies should test the efficacy of Tac 1 MMF in
less stringent conditions such as reduced intensity or
NM conditioning regimens, sibling donors, and
marrow transplants.ACKNOWLEDGMENTS
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